AstraZeneca Seeks US FDA Approval for Lung Drug
AstraZeneca has applied for US Food and Drug Administration approval of the ORPATHYS and TAGRISSO drug combination. The treatment targets advanced lung cancer patients who progressed after prior therapy. The combination successfully extended progression-free survival compared to chemotherapy.
Xurve View
Insights:
Xurve View
ASTRAZENECA PLC filed for United States regulatory approval of an advanced lung cancer drug combination. The application covers the ORPATHYS-TAGRISSO therapy developed with HUTCHMED CHINA-ADR. It targets patients whose disease progressed after prior epidermal growth factor receptor therapies.
